1Department of Cardiology, Division of Electrophysiology, University Heart Center Zurich,
Switzerland; 2Age-Related Health Care, Tallaght University Hospital/Department of …

In 2018, the International Council for Standardization in Haematology (ICSH) published a
consensus document providing guidance for laboratories on measuring direct oral …

This guidance document was prepared on behalf of the International Council for
Standardization in Haematology (ICSH) for providing haemostasis-related guidance …

This study aimed to analyze associations between genetic variants and the occurrence of
clinical outcomes in dabigatran, apixaban, and rivaroxaban users. This was a retrospective …

Cardiovascular disease is an emerging medical issue in patients with hemophilia (PWH)
and its prevalence is increasing up to 15% in PWH in the United States. Atrial fibrillation …

Background Emerging safety and efficacy data for rivaroxaban suggest traditional therapy
and rivaroxaban are comparable in the morbidly obese. However, real‐world data that …

Factor Xa-inhibitor apixaban is an oral anticoagulant prescribed in atrial fibrillation (AF) for
stroke prevention. Its pharmacokinetic profile is known to be affected by cytochrome P450 …

Anticoagulation is central to the management of thrombotic antiphospholipid syndrome
(APS). The standard anticoagulant treatment for thrombotic APS is life‐long warfarin or an …

Snake venoms have evolved primarily to immobilize and kill prey, and consequently, they
contain some of the most potent natural toxins. Part of that armory is a range of hemotoxic …

In some clinical situations, measurements of anticoagulant effect of apixaban may be
needed. We investigated the inter-and intra-individual apixaban variability in patients with …